Patient Invoice Payment Link
Contact Us

Advanced UTI PCR Panel

Comprehensive, Rapid, and Clinically Actionable Detection

Rethinking UTI Diagnosis

Urinary tract infections (UTIs) are among the most common infections—but also among the most frequently misdiagnosed and undertreated due to:

  • Limitations of traditional urine culture
  • Polymicrobial infections
  • Fastidious and slow-growing organisms

Our multiplex UTI PCR panel delivers rapid, highly sensitive detection of pathogens and resistance markers, enabling clinicians to make faster, more accurate treatment decisions.

Urinary Tract Infection (UTI) Pathogen Panel

Bacteria
23 targets
Acinetobacter baumannii
Bac (gram-negative)
Actinotignum schaalii
Bac (gram-negative)
Aerococcus urinae
Bac (gram-negative)
Bacteroides fragilis
Bac (gram-negative)
Citrobacter spp. (freundii/braakii/koseri)
Bac (gram-negative)
Enterobacter cloacae
Bac (gram-negative)
Enterococcus faecalis
Bac (gram-negative)
Enterococcus faecium
Bac (gram-negative)
Escherichia coli
Bac (gram-negative)
Klebsiella (Enterobacter) aerogenes
Bac (gram-negative)
Klebsiella oxytoca
Bac (gram-negative)
Klebsiella pneumoniae
Bac (gram-negative)
Morganella morganii
Bac (gram-negative)
Prevotella bivia
Bac (gram-negative)
Proteus mirabilis
Bac (gram-negative)
Proteus vulgaris
Bac (gram-negative)
Pseudomonas aeruginosa
Bac (gram-negative)
Serratia marcescens
Bac (gram-negative)
Staphylococcus aureus
Bac (gram-positive)
Staphylococcus haemolyticus
Bac (gram-positive)
Staphylococcus saprophyticus
Bac (gram-positive)
Streptococcus agalactiae (Group-B)
Bac (gram-positive)
Streptococcus pyogenes (Group-A)
Bac (gram-positive)
Fungus
7 targets
Candida albicans
Fungus
Candida auris
Fungus
Candida glabrata
Fungus
Candida parapsilosis
Fungus
Candida tropicalis
Fungus
Epidermophyton floccosum
Fungus
Trichophyton rubrum
Fungus
AMR
15 targets
Class A beta-lactamase resistance (blaSHV)
AMR
Class A beta-lactamase resistance (blaTEM)
AMR
Class A beta-lactamase resistance (CTX-M-Grp1)
AMR
Class B beta-lactamase resistance (blaNDM-1/blaNDM-4/blaNDM-5/blaNDM-7)
AMR
Class D beta-lactamase resistance (OXA-48/OXA-51)
AMR
Fluoroquinolone resistance (gyrA)
AMR
Fluoroquinolone resistance (qnrA/qnrB/qnrS)
AMR
Methicillin resistance (mecA)
AMR
Sulfonamide resistance (sul1)
AMR
Tetracycline resistance (tetB)
AMR
Tetracycline resistance (tetM)
AMR
Trimethoprim resistance (dfrA1)
AMR
Vancomycin resistance (vanA)
AMR
Vancomycin resistance (vanB)
AMR
Vancomycin resistance (vanM)
AMR

Comprehensive Pathogen Coverage

Bacterial Pathogens

Covers both common and emerging uropathogens, including:

  • Escherichia coli
  • Klebsiella pneumoniae, K. oxytoca
  • Proteus mirabilis, P. vulgaris
  • Enterococcus faecalis, E. faecium
  • Pseudomonas aeruginosa
  • Staphylococcus saprophyticus, S. aureus
  • Streptococcus agalactiae (Group B)

Plus fastidious and often underdiagnosed organisms:

  • Actinotignum schaalii
  • Aerococcus urinae
  • Anaerobes such as Bacteroides fragilis and Prevotella bivia

Full bacterial panel detailed on page 1

Fungal Pathogens

Important for complicated and catheter-associated UTIs:

  • Candida albicans, C. glabrata, C. tropicalis
  • Emerging pathogen: Candida auris
  • Dermatophytes (Trichophyton rubrum, Epidermophyton floccosum)

Fungal targets listed on page 1

Integrated Antimicrobial Resistance (AMR) Detection

Identifies genes associated with treatment failure and multidrug resistance:

  • ESBLs & beta-lactamases: blaTEM, blaSHV, CTX-M
  • Carbapenem resistance: NDM variants, OXA-48/51
  • Fluoroquinolone resistance: gyrA, qnr genes
  • Methicillin resistance: mecA
  • Vancomycin resistance: vanA, vanB, vanM
  • Other resistance markers: sul1, tetB, tetM, dfrA1

AMR targets detailed across pages 1–2

Clinical Utility — Why This Panel Matters

1. Detects Polymicrobial UTIs

  • Up to 30–50% of UTIs may involve multiple organisms
  • PCR identifies all pathogens in a single test, including:
  • Aerobes and anaerobes
  • Fastidious organisms missed by culture

2. Overcomes Limitations of Urine Culture

  • Traditional culture:
  • Misses low bacterial loads
  • Fails to grow certain organisms
  • Delays results (48–72+ hours)
  • PCR provides:
  • Higher sensitivity
  • Detection of non-culturable pathogens
  • Results in ~24 hours

3. Enables Targeted Antibiotic Therapy

  • Direct identification of pathogens + resistance genes
  • Reduces:
  • Empiric broad-spectrum antibiotic use
  • Trial-and-error prescribing
  • Improves:
  • Clinical outcomes
  • Antibiotic stewardship

4. Ideal for Complicated & Recurrent UTIs

  • Especially valuable in:
  • Recurrent UTIs
  • Catheter-associated infections
  • Elderly and long-term care patients
  • Patients with persistent symptoms but negative cultures

5. Detects Emerging & Overlooked Pathogens

  • Organisms like:
  • Actinotignum schaalii
  • Aerococcus urinae
  • Frequently missed but clinically significant in:
  • Older adults
  • Chronic infections

6. Identifies Fungal Involvement

  • Important in:
  • Immunocompromised patients
  • Catheterized individuals
  • Prevents misclassification as bacterial-only infections

Clinical Scenarios Where This Panel Excels

Recurrent UTI with negative or inconsistent cultures

Persistent symptoms despite antibiotic therapy

Complicated UTIs in LTC or hospitalized patients

Suspected multidrug-resistant infections

Polymicrobial or atypical presentations

Key Advantages at a Glance

Broad pathogen detection (bacteria + fungi)

Integrated AMR profiling

Rapid turnaround (~24 hours)

High sensitivity vs. culture

Detects polymicrobial infections

Supports precision medicine

Elevating UTI Management

This UTI PCR panel enables providers to:

Make faster, evidence-based diagnoses

Prescribe targeted, effective therapies

Reduce treatment failures and recurrence

Improve patient satisfaction and outcomes